Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.
April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy
March 25th 2024- Prof. Olaf Penack- Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation
March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
March 11th 2024- Dr. Adi Zoref Lorenz – Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Sweden: Incidence, Clinical Characteristics, and Survival
March 6th 2024- Prof. Katy Rezvani – Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: a Phase 1/2 Trial
Feb 26th 2024- Prof. Marion Subklewe- Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Feb 23rd 2024- Guido Ghilardi & Marco Ruella- T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy
Feb 14th 2024- Dr. Joshua Fein- Simple Score of Albumin and CRP Predicts High Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
Feb 5th 2024- Prof. Ali Bazarbachi- Sorafenib Plus Intensive Chemotherapy in Newly Diagnosed FLT3-ITD AML: A Randomized, Placebo-Controlled Study by the ALLG
Feb 2nd 2024- Dr. Paula Rodriguez-Otero- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization approval for idecabtagene vicleucel (Abecma; ide-cel) for use in adult patients with relapsed and refractory multiple myeloma who previously received at least 2 therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody
Jan 23rd 2024- Prof. Daniel Wolff- Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with CGVHD Disease (AGAVE-201)
Jan 8th 2024- David Valcarcel & Adrian Mosquera- Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
Dec 19th 2023- Prof. Florent Malard- Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as a Predictor of Mortality in Children
Dec 12th 2023- Prof. Arnold Ganser – How I Treat Refractory and Relapsed Acute Myeloid Leukemia
Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study
Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry
Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial
Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia
Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD
Oct 30th 2023- Prof. Robert Zeiser- Phase 2 Study of Natalizumab Plus Standard Corticosteroid Treatment for High-Risk Acute GVHD
Oct 23rd 2023- Prof. Didier Blaise- Real World Experience of CAR T Cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Oct 16th 2023- Dr. Enrique Ocio- Melflufen Plus Dexamethasone and Daratumumab or Bortezomib in Relapsed/Refractory MM
Oct 9th 2023- Dr. Philippe Armand- Five-year follow-up of KEYNOTE-087
Oct 2nd 2023- Dr. Paul Richardson- Mezigdomide plus Dexamethasone in Relapsed and Refractory Myeloma
Sept 25th 2023- Dr. Akshay Sharma- CRISPR- Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease
Sept 19th 2023- Prof. Ephraim Fuchs- Cytokine Release Syndrome in Haploidentical Stem Cell Transplant May Impact T-cell Recovery and Relapse
Sept 12th 2023- Prof. Christina Peters- Poverty and Relapse Risk in Children with ALL: A Children’s Oncology Group Study AALL03N1 Report
Sept 7th 2023- Prof. Alvaro Urbano- Fractionated Initial Infusion and Booster Dose of ARI0002h, a Humanised, BCMA-Directed CAR T-cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma (CARTBCMA-HCB-01): a Single-Arm, Multicentre, Academic Pilot Study
Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions
Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL
Aug 21st 2023- Dr. Ashwin Kishtagari- His Take on the Recent Approval of Quizartinib by FDA in AML
Aug 16th 2023- Dr. Jayastu Senapati- Prognostic Impact of Splicing Factor Mutations in Patients with Newly Diagnosed AML
Aug 8th 2023- Dr. Tania Jain- Haploidentical Donor Hematopoietic Cell Transplantation for MDS/MPN Overlap Neoplasms: Results from a North American Collaboration
Aug 1st 2023- Dr. Samer Al Hadidi- Risk of Infections Associated with the use of Bispecific Antibodies in Multiple Myeloma
July 25th 2023- Dr. Olalekan Oluwole- His Take on the Overall Survival Update from the Randomized ZUMA-7 Trial
July 17th 2023- Dr. Jordan Gauthier- CD19 CAR T-Cell Therapy & Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results
July 7th 2023- Bu-Flu Versus Bu-Cy for AML Patients Undergoing Haplo: a Multi Center Randomized Phase III Trial by Ling Yiwen and Colleagues
May 9th 2023- Dr. Olalekan Oluwole – Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL
May 5th 2023- Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation
Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy
Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Prof. Florent Malard- The First microbiota therapy approved by the US FDA
Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure
Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma
Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Prof. Mohamed Kharfan Dabaja – Positive Results from Final Progression-Free Survival Analysis of zanubrutinib Compared to ibrutinib in CLL
Dr. Areej El-Jawahri – Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
Prof. He Huang – Non-viral, specifically targeted CAR-T cells, achieve high safety and efficacy in B-NHL
Prof. Mikkael Sekeres – Azacitidine plus venetoclax for myelodysplastic syndromes
Dr. Adi Nagler – Single cell sequencing to chronic lymphocytic leukemia
Prof. Meral Beksac – The recent developments in the field of bispecific T-cell engagers
Prof. Selim Corbacioglu – The importance of veno-occlusive disease prophylaxis
Prof. Paul Richardson – Melflufen for the treatement of relapsed-refractory myeloma
Prof. Mohamad Mohty – New treatments for refractrory acute GVHD
Dr. Eolia Brissot – Approval of maribvir for post-transplant cytomegalovirus infection
Prof. Sebastian Giebel – CAR T cells for adult ALL
Prof. Farhad Ravandi – MRD in AML
Prof. Iskra Pusic – Recent updated in Acute GVHD
Prof. Arnon Kater -State of the art therapy in CLL
Annalisa Ruggeri – Haplo versus matched unrelated transplant at the era of post-cyclophosphamide
Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?
Robert Zeiser – REACH3 trial results
Alex Lazaryan – Belumosudil’s FDA approval for cGVHD
Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting
Naveen Pemmaraju – Novel Therapeutic Approaches in BPDCN
Jurgen Kuball – Gammadelta T cells
Anna Sureda – Therapy of lymphomas, what’s new at EHA 2021
Nitin Jain – Therapy of CLL, what’s new at EHA 2021
Gram Jackson – Recently released paper on Improving prognostic assignment in older adults with MM
Mehdi Hamadani – Recently released ZUMA-7 trial results
Saad Usmani – Take-home messages, from ASCO, and EHA 2021
Luciano J. Costa – The role of auto in myeloma based on the ASCO 21 data
Jesus G. Berdeja – Results of the CARTITUDE-1 study
Arnon Nagler – Allo-transplant for AML: what’s new at EHA 2021
Mohamad Mohty – Advances in Multiple Myeloma as reported at EHA 2021
Ruben Mesa – Therapy of MPNs: what’s new at EHA 2021?
Dr. Jordan Gauthier – Results from Phase 3 TRANSFORM Trial
Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021
Prof. Mohamad Mohty – Multiple myeloma take home messages from ASCO 2021
